Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 - the first ever CDK8 inhibitor for acute myeloid leukaemia with great opportunities for further indications and development. Furthermore, he highlights the company’s diverse services offered to external partners as well as the potential for Poland to be a larger player in the global biotech landscape and driving forward the domestic R&D movement.
As the CEO, what have been Selvita’s major achievements over the last year?
"We create a level playing field from an economic point of view, by offering competitive salaries and low taxes, coupled with the Polish low cost of living."
